Christopher R.  Loose net worth and biography

Christopher Loose Biography and Net Worth

Chris has served as Frequency’s Chief Scientific Officer since co-founding the company in 2014. Before joining Frequency, he served as Chief Technology Officer for Semprus BioSciences, a company he also co-founded and was acquired by Teleflex in 2012. During his tenure at Semprus, he led the technology team in developing medical products with surface modifications designed to reduce infection and clotting, leading to FDA and European CE marketing clearance.

Prior to Semprus, Chris worked as a chemical engineer at Merck Research Labs. In 2011, Chris was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. He has also been named to the MIT Technology Review 35, the 35 innovators under 35 most likely to impact technology, and the Boston Business Journal 40 under 40. He is currently the Executive Director of Yale University’s Center for Biomedical and Interventional Technology (CBIT), and Associate Adjunct Professor of Urology in the Yale School of Medicine.

Chris holds a Ph.D. in Chemical Engineering from MIT, where he was a Hertz Fellow and studied under Robert Langer, Sc.D. Previously, he earned a B.S.E in Chemical Engineering summa cum laude from Princeton University.

What is Christopher R. Loose's net worth?

The estimated net worth of Christopher R. Loose is at least $55,021.54 as of July 28th, 2023. Dr. Loose owns 183,650 shares of Frequency Therapeutics stock worth more than $55,022 as of March 29th. This net worth approximation does not reflect any other investments that Dr. Loose may own. Learn More about Christopher R. Loose's net worth.

How do I contact Christopher R. Loose?

The corporate mailing address for Dr. Loose and other Frequency Therapeutics executives is 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801. Frequency Therapeutics can also be reached via phone at 781-315-4600 and via email at [email protected]. Learn More on Christopher R. Loose's contact information.

Has Christopher R. Loose been buying or selling shares of Frequency Therapeutics?

Christopher R. Loose has not been actively trading shares of Frequency Therapeutics during the last ninety days. Most recently, Christopher R. Loose sold 1,344 shares of the business's stock in a transaction on Friday, July 28th. The shares were sold at an average price of $0.46, for a transaction totalling $618.24. Following the completion of the sale, the insider now directly owns 183,650 shares of the company's stock, valued at $84,479. Learn More on Christopher R. Loose's trading history.

Who are Frequency Therapeutics' active insiders?

Frequency Therapeutics' insider roster includes Carl LeBel (Insider), Christopher Loose (Insider), Quentin McCubbin (Insider), and Peter Pfreundschuh (CFO). Learn More on Frequency Therapeutics' active insiders.

Are insiders buying or selling shares of Frequency Therapeutics?

During the last twelve months, insiders at the sold shares 46 times. They sold a total of 65,319 shares worth more than $36,102.94. The most recent insider tranaction occured on August, 18th when VP Richard J Mitrano sold 227 shares worth more than $143.01. Insiders at Frequency Therapeutics own 16.8% of the company. Learn More about insider trades at Frequency Therapeutics.

Information on this page was last updated on 8/18/2023.

Christopher R. Loose Insider Trading History at Frequency Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/28/2023Sell1,344$0.46$618.24183,650View SEC Filing Icon  
7/26/2023Sell1,329$0.51$677.79186,367View SEC Filing Icon  
7/24/2023Sell1,438$0.54$776.52189,086View SEC Filing Icon  
7/21/2023Sell1,333$0.61$813.13190,524View SEC Filing Icon  
7/19/2023Sell1,335$0.65$867.75193,218View SEC Filing Icon  
7/17/2023Sell1,415$0.67$948.05196,037View SEC Filing Icon  
7/14/2023Sell906$0.59$534.54197,452View SEC Filing Icon  
7/12/2023Sell1,335$0.39$520.65199,687View SEC Filing Icon  
7/10/2023Sell1,304$0.37$482.4866,023View SEC Filing Icon  
7/6/2023Sell1,384$0.34$470.5657,758View SEC Filing Icon  
7/6/2022Sell4,415$1.53$6,754.9550,050View SEC Filing Icon  
2/22/2022Sell1,069$3.53$3,773.57View SEC Filing Icon  
2/18/2022Sell974$3.87$3,769.38View SEC Filing Icon  
2/3/2021Sell10,000$45.46$454,600.00
1/27/2021Sell8,000$42.50$340,000.0031,782View SEC Filing Icon  
12/16/2020Sell8,000$38.94$311,520.0063,782View SEC Filing Icon  
12/14/2020Sell8,000$35.00$280,000.0063,782View SEC Filing Icon  
11/9/2020Sell8,000$24.00$192,000.0079,782View SEC Filing Icon  
11/5/2020Sell8,000$23.00$184,000.0079,782View SEC Filing Icon  
10/13/2020Sell8,000$22.00$176,000.0087,782View SEC Filing Icon  
10/8/2020Sell24,000$20.19$484,560.00111,782View SEC Filing Icon  
10/5/2020Sell8,000$18.35$146,800.00135,782View SEC Filing Icon  
10/1/2020Sell8,000$18.84$150,720.00135,782View SEC Filing Icon  
9/23/2020Sell4,500$21.13$95,085.00146,412View SEC Filing Icon  
9/9/2020Sell4,500$18.97$85,365.00149,058View SEC Filing Icon  
8/19/2020Sell4,500$22.97$103,365.00152,782View SEC Filing Icon  
8/5/2020Sell4,500$21.21$95,445.00157,340View SEC Filing Icon  
7/22/2020Sell4,500$21.51$96,795.00161,782View SEC Filing Icon  
7/8/2020Sell4,500$22.32$100,440.00167,061View SEC Filing Icon  
6/24/2020Sell4,500$22.80$102,600.00170,782View SEC Filing Icon  
6/10/2020Sell4,500$19.96$89,820.00175,282View SEC Filing Icon  
5/20/2020Sell4,500$19.02$85,590.00189,114View SEC Filing Icon  
5/6/2020Sell4,500$16.28$73,260.00192,336View SEC Filing Icon  
4/22/2020Sell4,500$14.84$66,780.00196,282View SEC Filing Icon  
4/8/2020Sell4,500$14.99$67,455.00200,782View SEC Filing Icon  
See Full Table

Christopher R. Loose Buying and Selling Activity at Frequency Therapeutics

This chart shows Christopher R Loose's buying and selling at Frequency Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Frequency Therapeutics Company Overview

Frequency Therapeutics logo
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $0.30
Low: $0.28
High: $0.32

50 Day Range

MA: $0.58
Low: $0.22
High: $14.98

2 Week Range

Now: $0.30
Low: $0.18
High: $16.00

Volume

309,164 shs

Average Volume

822,537 shs

Market Capitalization

$10.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84